Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
Alejandro Gonzalez-Serna,1 Miguel Genebat,2 Ezequiel Ruiz-Mateos,2 Manuel Leal2 1Laboratory of Molecular Immunobiology, Hospital General Universitario Gregorio Maranon, Madrid, 2Laboratory of Immunovirology, Institute of Biomedicine of Seville, Seville, SpainWoollard and Kanmogne1 have generated an...
Saved in:
Main Authors: | Gonzalez-Serna A (Author), Genebat M (Author), Ruiz-Mateos E (Author), Leal M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015) -
Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020) -
Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
by: Jintanat Ananworanich, et al.
Published: (2015) -
Fármacos recentes usados para o tratamento da infecção pelo HIV-1: enfuvirtida, maraviroc, raltegravir e etravirina
by: M.A. Brito
Published: (2011) -
Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
by: S. Moreno, et al.
Published: (2019)